(NewsDirect)
ReNeuron Group PLC executive chairmanIain Ross tells Proactive that the company is focused on generating invivo data and validating its exosome delivery technology platformCustomEX as 2023 gets underway.
ReNeuron will conducthead-to-head studies with its competitors to produce the data neededto achieve the commercial validation of the platform, Ross said. Thecompany's cash runway has also been extended into 2024 following arestructuring undertaken in 2022, he added.
Contact Details
ProactiveUK Ltd
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.